ABL Bio FY 2025 Annual Report
Beta

Filed: March 12, 2026· period ending December 31, 2025DART

ABL Bio annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 12, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).

ABL Bio FY 2025 Annual Report Analysis

Business Overview

• KRW 79.35B revenue in FY2025 entirely from license-out of bispecific antibody, ADC, neurodegenerative treatments
• Grabody-B BBB shuttle platform licensed to GSK (Apr 2025) and Eli Lilly (Nov 2025) for global exclusive rights, total contracts USD 2.64B upfronts

Management Discussion & Analysis

• Revenue KRW 79.35B (+137.6% YoY), Operating loss KRW 40.39B (-32.0%), Net loss KRW 37.88B (-31.8%) in fiscal 2025
• License-out business drove revenue increase by KRW 4.59B, led by upfront payments from GSK (GBP 38.5M) and milestone recognition from Sanofi (USD 75M)

Risk Factors

• KRW 59.17B USD-denominated foreign currency assets and KRW 4.67B liabilities at FY2025-end
• KRW 9.69B pre-tax loss impact from 10% KRW depreciation against foreign currencies at FY2025-end

ABL Bio FY 2025 Key Financial Metrics
DART

Total Assets

KRW 280.9B

▲ +21.1% YoY

Operating Cash Flow

-KRW 41.3B

▲ +40.6% YoY

Source: KIFRS consolidated financial data from ABL Bio annual report on DART. All figures in KRW.

Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding